351 related articles for article (PubMed ID: 24992294)
1. Atazanavir exposure is effective during pregnancy regardless of tenofovir use.
Colbers A; Hawkins D; Hidalgo-Tenorio C; van der Ende M; Gingelmaier A; Weizsäcker K; Kabeya K; Taylor G; Rockstroh J; Lambert J; Moltó J; Wyen C; Sadiq ST; Ivanovic J; Giaquinto C; Burger D;
Antivir Ther; 2015; 20(1):57-64. PubMed ID: 24992294
[TBL] [Abstract][Full Text] [Related]
2. Tenofovir comedication does not impair the steady-state pharmacokinetics of ritonavir-boosted atazanavir in HIV-1-infected adults.
von Hentig N; Dauer B; Haberl A; Klauke S; Lutz T; Staszewski S; Harder S
Eur J Clin Pharmacol; 2007 Oct; 63(10):935-40. PubMed ID: 17665183
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of an increased atazanavir dose with and without tenofovir during the third trimester of pregnancy.
Kreitchmann R; Best BM; Wang J; Stek A; Caparelli E; Watts DH; Smith E; Shapiro DE; Rossi S; Burchett SK; Hawkins E; Byroads M; Cressey TR; Mirochnick M
J Acquir Immune Defic Syndr; 2013 May; 63(1):59-66. PubMed ID: 23392467
[TBL] [Abstract][Full Text] [Related]
4. Atazanavir pharmacokinetics with and without tenofovir during pregnancy.
Mirochnick M; Best BM; Stek AM; Capparelli EV; Hu C; Burchett SK; Rossi SS; Hawkins E; Basar M; Smith E; Read JS;
J Acquir Immune Defic Syndr; 2011 Apr; 56(5):412-9. PubMed ID: 21283017
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of total and unbound darunavir in HIV-1-infected pregnant women.
Colbers A; Moltó J; Ivanovic J; Kabeya K; Hawkins D; Gingelmaier A; Taylor G; Weizsäcker K; Sadiq ST; Van der Ende M; Giaquinto C; Burger D;
J Antimicrob Chemother; 2015 Feb; 70(2):534-42. PubMed ID: 25326090
[TBL] [Abstract][Full Text] [Related]
6. Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study.
Molina JM; Andrade-Villanueva J; Echevarria J; Chetchotisakd P; Corral J; David N; Moyle G; Mancini M; Percival L; Yang R; Thiry A; McGrath D;
Lancet; 2008 Aug; 372(9639):646-55. PubMed ID: 18722869
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics, safety and efficacy of ritonavir-boosted atazanavir (300/100 mg once daily) in HIV-1-infected pregnant women.
Lê MP; Mandelbrot L; Descamps D; Soulié C; Ichou H; Bourgeois-Moine A; Damond F; Lariven S; Valantin MA; Landman R; Faucher P; Tubiana R; Duro D; Meier F; Legac S; Bourse P; Mortier E; Dommergues M; Calvez V; Matheron S; Peytavin G
Antivir Ther; 2015; 20(5):507-13. PubMed ID: 25599649
[TBL] [Abstract][Full Text] [Related]
8. Atazanavir intracellular concentrations remain stable during pregnancy in HIV-infected patients.
Focà E; Calcagno A; Bonito A; Simiele M; Domenighini E; D'Avolio A; Quiros Roldan E; Trentini L; Casari S; Di Perri G; Castelli F; Bonora S
J Antimicrob Chemother; 2017 Nov; 72(11):3163-3166. PubMed ID: 28961777
[TBL] [Abstract][Full Text] [Related]
9. Clinical pharmacokinetics and summary of efficacy and tolerability of atazanavir.
Le Tiec C; Barrail A; Goujard C; Taburet AM
Clin Pharmacokinet; 2005; 44(10):1035-50. PubMed ID: 16176117
[TBL] [Abstract][Full Text] [Related]
10. Dual treatment with atazanavir-ritonavir plus lamivudine versus triple treatment with atazanavir-ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT): 48 week results from a randomised, open-label, non-inferiority trial.
Perez-Molina JA; Rubio R; Rivero A; Pasquau J; Suárez-Lozano I; Riera M; Estébanez M; Santos J; Sanz-Moreno J; Troya J; Mariño A; Antela A; Navarro J; Esteban H; Moreno S;
Lancet Infect Dis; 2015 Jul; 15(7):775-84. PubMed ID: 26062881
[TBL] [Abstract][Full Text] [Related]
11. Abacavir plasma pharmacokinetics in the absence and presence of atazanavir/ritonavir or lopinavir/ritonavir and vice versa in HIV-infected patients.
Waters LJ; Moyle G; Bonora S; D'Avolio A; Else L; Mandalia S; Pozniak A; Nelson M; Gazzard B; Back D; Boffito M
Antivir Ther; 2007; 12(5):825-30. PubMed ID: 17713166
[TBL] [Abstract][Full Text] [Related]
12. Low-dose versus standard-dose ritonavir-boosted atazanavir in virologically suppressed Thai adults with HIV (LASA): a randomised, open-label, non-inferiority trial.
Bunupuradah T; Kiertiburanakul S; Avihingsanon A; Chetchotisakd P; Techapornroong M; Leerattanapetch N; Kantipong P; Bowonwatanuwong C; Banchongkit S; Klinbuayaem V; Mekviwattanawong S; Nimitvilai S; Jirajariyavej S; Prasithsirikul W; Munsakul W; Bhakeecheep S; Chaivooth S; Phanuphak P; Cooper DA; Apornpong T; Kerr SJ; Emery S; Ruxrungtham K;
Lancet HIV; 2016 Aug; 3(8):e343-e350. PubMed ID: 27470026
[TBL] [Abstract][Full Text] [Related]
13. Safety and exposure of once-daily ritonavir-boosted atazanavir in HIV-infected pregnant women.
Conradie F; Zorrilla C; Josipovic D; Botes M; Osiyemi O; Vandeloise E; Eley T; Child M; Bertz R; Hu W; Wirtz V; McGrath D
HIV Med; 2011 Oct; 12(9):570-9. PubMed ID: 21569187
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of once-daily ritonavir-boosted atazanavir or darunavir in combination with a dual nucleos(t)ide analogue backbone in HIV-1-infected combined ART (cART)-naive patients with severe immunosuppression: a 48 week, non-comparative, randomized, multicentre trial (IMEA 040 DATA trial).
Slama L; Landman R; Assoumou L; Benalycherif A; Samri A; Joly V; Pialoux G; Valin N; Cabié A; Duvivier C; Lambert-Niclot S; Marcelin AG; Peytavin G; Costagliola D; Girard PM;
J Antimicrob Chemother; 2016 Aug; 71(8):2252-61. PubMed ID: 27068399
[TBL] [Abstract][Full Text] [Related]
15. The effects of a nucleoside-sparing antiretroviral regimen on the pharmacokinetics of ritonavir-boosted darunavir in HIV type-1-infected patients.
Garvey L; Latch N; Erlwein OW; Mackie NE; Walsh J; Scullard G; McClure MO; Dickinson L; Back D; Winston A
Antivir Ther; 2010; 15(2):213-8. PubMed ID: 20386076
[TBL] [Abstract][Full Text] [Related]
16. Treatment response to unboosted atazanavir in combination with tenofovir disoproxil fumarate and lamivudine in human immunodeficiency virus-1-infected patients who have achieved virological suppression: A therapeutic drug monitoring and pharmacogenetic study.
Tsai MS; Chang SY; Lin SW; Kuo CH; Sun HY; Wu BR; Tang SY; Liu WC; Su YC; Hung CC; Chang SC
J Microbiol Immunol Infect; 2017 Dec; 50(6):789-797. PubMed ID: 26857335
[TBL] [Abstract][Full Text] [Related]
17. Influence of tenofovir, nevirapine and efavirenz on ritonavir-boosted atazanavir pharmacokinetics in HIV-infected patients.
Dailly E; Tribut O; Tattevin P; Arvieux C; Perré P; Raffi F; Jolliet P
Eur J Clin Pharmacol; 2006 Jul; 62(7):523-6. PubMed ID: 16763827
[TBL] [Abstract][Full Text] [Related]
18. Atazanavir plus low-dose ritonavir in pregnancy: pharmacokinetics and placental transfer.
Ripamonti D; Cattaneo D; Maggiolo F; Airoldi M; Frigerio L; Bertuletti P; Ruggeri M; Suter F
AIDS; 2007 Nov; 21(18):2409-15. PubMed ID: 18025877
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of antiretroviral regimens containing tenofovir disoproxil fumarate and atazanavir-ritonavir in adolescents and young adults with human immunodeficiency virus infection.
Kiser JJ; Fletcher CV; Flynn PM; Cunningham CK; Wilson CM; Kapogiannis BG; Major-Wilson H; Viani RM; Liu NX; Muenz LR; Harris DR; Havens PL;
Antimicrob Agents Chemother; 2008 Feb; 52(2):631-7. PubMed ID: 18025112
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of ritonavir-boosted and unboosted atazanavir among antiretroviral-naïve patients.
Horberg M; Klein D; Hurley L; Silverberg M; Towner W; Antoniskis D; Kovach D; Mogyoros M; Blake W; Dobrinich R; Dodge W
HIV Clin Trials; 2008; 9(6):367-74. PubMed ID: 19203902
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
